Covered recipient · General Payments record
WALID L SHAIB
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$32,922.91
147 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $11,220.00 | 5 |
| Consulting Fee | $9,550.00 | 10 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,082.50 | 5 |
| Food and Beverage | $2,999.56 | 115 |
| Honoraria | $2,825.00 | 1 |
| Travel and Lodging | $1,120.79 | 8 |
| Education | $125.06 | 3 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WALID L SHAIB
NPI 1831372481 · CMS profile ID 1241130
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NEW HAVEN, CT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1831372481?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WALID L SHAIB, NPI 1831372481, CMS profile ID 1241130. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831372481?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). WALID L SHAIB, NPI 1831372481, CMS profile ID 1241130. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831372481?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- WALID L SHAIB, NPI 1831372481, CMS profile ID 1241130, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1831372481?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
147 matching records · $32,922.91 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 147.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | $165.82 | 09/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1092250896 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 09/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104386671 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 09/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105875667 | CMS |
| Eisai Inc. | $18.73 | 09/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110788009 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.23 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144967151 | CMS |
| PFIZER INC. | $129.30 | 09/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132023813 | CMS |
| Rigel Pharmaceuticals, Inc. | $16.68 | 09/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145208963 | CMS |
| ABBVIE INC. | $25.27 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106069816 | CMS |
| Merck Sharp & Dohme LLC | $18.61 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141817571 | CMS |
| AstraZeneca Pharmaceuticals LP | $525.00 | 08/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104729073 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.93 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105469395 | CMS |
| ABBVIE INC. | $18.76 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106069814 | CMS |
| ARRAY BIOPHARMA INC | $21.53 | 08/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131984761 | CMS |
| SOBI, INC | $200.00 | 08/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141422229 | CMS |
| PFIZER INC. | $15.61 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131939961 | CMS |
| AstraZeneca Pharmaceuticals LP | $525.00 | 08/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104353122 | CMS |
| PFIZER INC. | $9.68 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131370280 | CMS |
| Genentech USA, Inc. | $23.80 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133131185 | CMS |
| Merck Sharp & Dohme LLC | $30.00 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141817759 | CMS |
| Celgene Corporation | $18.65 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101156756 | CMS |
| GENZYME CORPORATION | $41.69 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139986974 | CMS |
| SOBI, INC | $35.53 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141419682 | CMS |
| Merck Sharp & Dohme LLC | $21.07 | 07/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141817753 | CMS |
| PFIZER INC. | $15.38 | 07/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131923487 | CMS |
| Daiichi Sankyo Inc. | $26.36 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089481229 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.91 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105651836 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.25 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105860634 | CMS |
| AstraZeneca Pharmaceuticals LP | $525.00 | 06/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104718823 | CMS |
| Novartis Pharmaceuticals Corporation | $22.29 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087293643 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.25 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101568289 | CMS |
| Eisai Inc. | $20.33 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110788013 | CMS |
| ARRAY BIOPHARMA INC | $14.05 | 06/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131918809 | CMS |
| Gilead Sciences, Inc. | $19.50 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133796393 | CMS |
| PFIZER INC. | $16.88 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131328801 | CMS |
| ABBVIE INC. | $32.86 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106069812 | CMS |
| Celgene Corporation | $16.83 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101156752 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.94 | 05/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144967149 | CMS |
| Rigel Pharmaceuticals, Inc. | $16.98 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145197885 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.85 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101568277 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.30 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104619068 | CMS |
| Deciphera Pharmaceuticals Inc. | $22.47 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145875193 | CMS |
| Gilead Sciences, Inc. | $15.00 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133796391 | CMS |
| PFIZER INC. | $19.09 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131920517 | CMS |
| Novartis Pharmaceuticals Corporation | $24.30 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087293649 | CMS |
| Novartis Pharmaceuticals Corporation | $24.62 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087293631 | CMS |
| Merck Sharp & Dohme LLC | $19.26 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141905184 | CMS |
| BeiGene USA, Inc. | $17.93 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120856935 | CMS |
| Regeneron Healthcare Solutions, Inc. | $24.23 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114168527 | CMS |
| Novartis Pharmaceuticals Corporation | $13.67 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087293669 | CMS |
| Janssen Biotech, Inc. | $13.07 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078381100 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $757,251.76 | 35 |
| PY2023 | Principal investigator | $7,941.75 | 2 |
| PY2022 | Principal investigator | $376,337.63 | 9 |
| PY2021 | Principal investigator | $293,000.00 | 3 |
| PY2020 | Principal investigator | $66,823.55 | 3 |
| PY2019 | Principal investigator | $226,121.05 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
35 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,792.20 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations | No dispute reported | 06/30/2026 | 1232923262 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,436.59 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers PC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 | No dispute reported | 06/30/2026 | 1232925961 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $18,435.62 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers PC | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926697 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,750.98 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers PC | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926699 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,263.62 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232934940 |
| Principal investigator 1 | Exelixis Inc. | $338.00 | 12/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382844 |
| Principal investigator 1 | Exelixis Inc. | $8,088.00 | 12/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382848 |
| Principal investigator 1 | Genentech, Inc. | $1,336.00 | 12/19/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211631383 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,425.00 | 12/17/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 | No dispute reported | 06/30/2026 | 1185548117 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $34,242.00 | 12/09/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, PC | Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | No dispute reported | 06/30/2026 | 1235995205 |
| Principal investigator 1 | Exelixis Inc. | $3,631.85 | 12/05/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382846 |
| Principal investigator 1 | Genentech, Inc. | $4,550.00 | 12/04/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211631440 |
| Principal investigator 1 | Genentech, Inc. | $908.00 | 12/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CEN | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211631347 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $217,137.00 | 11/25/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190303221 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,765.00 | 11/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) | No dispute reported | 06/30/2026 | 1185548120 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 11/20/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202525054 |
| Principal investigator 1 | Exelixis Inc. | $4,966.60 | 11/07/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382842 |
| Principal investigator 1 | Exelixis Inc. | $338.00 | 10/02/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382838 |
| Principal investigator 1 | Exelixis Inc. | $9,078.00 | 10/02/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382840 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,854.10 | 10/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190300105 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,265.00 | 09/30/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185548115 |
| Principal investigator 1 | Genentech, Inc. | $6,366.00 | 09/22/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211631437 |
| Principal investigator 1 | Exelixis Inc. | $2,595.40 | 09/19/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382836 |
| Principal investigator 1 | Exelixis Inc. | $2,530.80 | 09/05/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382834 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,686.49 | 08/26/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, PC | Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | No dispute reported | 06/30/2026 | 1235995207 |
| Principal investigator 1 | ABBVIE INC. | $18,690.00 | 08/06/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202502556 |
| Principal investigator 1 | Genentech, Inc. | $259.20 | 08/05/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211631509 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $240,432.99 | 07/31/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190305017 |
| Principal investigator 1 | Genentech, Inc. | $2,528.00 | 07/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211631379 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 07/03/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631501 |
| Principal investigator 1 | Genentech, Inc. | $3,300.00 | 07/03/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631504 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 07/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211631513 |
| Principal investigator 1 | Eli Lilly and Company | $765.00 | 06/03/2025 | Non-covered Recipient Entity NW GA ONCOLOGY CENTERS PC | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187885098 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $50,947.00 | 02/13/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Center, P.c. | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235995217 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $299.32 | 01/27/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, PC | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235995209 |